Clinical Trials Logo
  1. Home
  2. Central Precocious Puberty
  3. NCT01467882

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Central Precocious Puberty Clinical Trial

Official title:
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty

Clinical Trial Summary

The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01467882
Study type Interventional
Source Debiopharm International SA
Contact
Status Completed
Phase Phase 3
Start date April 2012
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02920515 - Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Phase 4
Completed NCT00779103 - Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Phase 3
Not yet recruiting NCT05341128 - A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China
Completed NCT04736602 - Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. Phase 3
Recruiting NCT05341115 - A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty Phase 4
Completed NCT02993926 - A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
Recruiting NCT02811471 - Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty Phase 3
Completed NCT03316482 - Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty Phase 4
Recruiting NCT06129539 - A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty Phase 3
Completed NCT01634321 - The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Phase 4
Terminated NCT02006680 - Markers of Pubertal Suppression During Therapy for Precocious Puberty
Completed NCT01278290 - Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Phase 3
Completed NCT02427958 - A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants Phase 4
Completed NCT05029622 - A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. Phase 3
Recruiting NCT06025409 - Evaluate the Efficacy and Safety of DWJ108J Phase 3
Recruiting NCT00438217 - Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Phase 4